ES2398646T3 - Estabilización de la interleuquina-6 en soluciones de suero - Google Patents

Estabilización de la interleuquina-6 en soluciones de suero Download PDF

Info

Publication number
ES2398646T3
ES2398646T3 ES10007718T ES10007718T ES2398646T3 ES 2398646 T3 ES2398646 T3 ES 2398646T3 ES 10007718 T ES10007718 T ES 10007718T ES 10007718 T ES10007718 T ES 10007718T ES 2398646 T3 ES2398646 T3 ES 2398646T3
Authority
ES
Spain
Prior art keywords
compound
serum
composition
concentration
ttab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10007718T
Other languages
English (en)
Spanish (es)
Inventor
Christian Dr. Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2398646T3 publication Critical patent/ES2398646T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES10007718T 2010-07-24 2010-07-24 Estabilización de la interleuquina-6 en soluciones de suero Active ES2398646T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10007718A EP2415461B1 (en) 2010-07-24 2010-07-24 Stabilization of interleukin 6 in serum based solutions

Publications (1)

Publication Number Publication Date
ES2398646T3 true ES2398646T3 (es) 2013-03-20

Family

ID=43063518

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10007718T Active ES2398646T3 (es) 2010-07-24 2010-07-24 Estabilización de la interleuquina-6 en soluciones de suero

Country Status (4)

Country Link
US (1) US8377882B2 (https=)
EP (1) EP2415461B1 (https=)
JP (1) JP5751965B2 (https=)
ES (1) ES2398646T3 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3605097B1 (en) * 2017-03-27 2024-11-13 NH Foods Ltd. Substance that prevents antigen-antibody reaction inhibition by body fluid
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
CN113614477B (zh) 2019-03-14 2023-04-28 泰尔茂比司特生物技术有限公司 冷冻干燥装载托盘组件及系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
DE3939706C1 (https=) 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
DE4022878A1 (de) 1990-07-18 1992-01-23 Boehringer Mannheim Gmbh Konservierung von diagnostischen tests
DE19746868A1 (de) * 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
US20050089918A1 (en) * 1998-02-23 2005-04-28 Amersham Biosciences Uk Limited In-situ cell extraction and assay method
KR100771294B1 (ko) * 1999-12-14 2007-10-29 써모 바이오스타, 인크. 폴리펩티드 및 항원 안정화 희석제
EP2236618A3 (en) * 2001-01-31 2011-06-08 Asahi Kasei Pharma Corporation Compositions for assaying glycoprotein
JP4453999B2 (ja) * 2001-02-14 2010-04-21 栄研化学株式会社 尿中蛋白及びペプチドの安定化方法
US7601491B2 (en) 2003-02-06 2009-10-13 Becton, Dickinson And Company Pretreatment method for extraction of nucleic acid from biological samples and kits therefor
MXPA05001815A (es) 2004-02-20 2005-08-24 Hoffmann La Roche Adsorcion de acidos nucleicos a una fase solida.
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
DE602006005806D1 (de) 2006-07-28 2009-04-30 Vista Ventures Gmbh Verfahren zum Nachweis der amyloid-beta Oligomere in Körperflüssigkeiten
WO2009048962A1 (en) 2007-10-12 2009-04-16 Vladislav Dolnik Capillary sieving electrophoresis with a cationic surfactant for size separation of proteins
CN102089319B (zh) * 2008-05-08 2013-11-13 味之素株式会社 蛋白质的重折叠方法

Also Published As

Publication number Publication date
EP2415461A8 (en) 2012-04-04
JP2012025749A (ja) 2012-02-09
JP5751965B2 (ja) 2015-07-22
EP2415461B1 (en) 2012-10-31
US20120107953A1 (en) 2012-05-03
US8377882B2 (en) 2013-02-19
EP2415461A1 (en) 2012-02-08

Similar Documents

Publication Publication Date Title
Reiss et al. Interleukin-6 in atherosclerosis: atherogenic or atheroprotective?
KR101042660B1 (ko) 안정한 액체 인터페론 제제
EP3290046B1 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
EP3701968A1 (en) Stable aqueous formulations of adalimumab
CN107412743B (zh) 通过施用重组vwf治疗凝血疾病
Shaker et al. Inducible nitric oxide synthase (iNOS) in gingival tissues of chronic periodontitis with and without diabetes: immunohistochemistry and RT-PCR study
AU2018308773B2 (en) IL-15 protein complex pharmaceutical composition and uses thereof
WO2008145323A1 (en) Pharmaceutical formulation for interferons
ES2398646T3 (es) Estabilización de la interleuquina-6 en soluciones de suero
US20230414717A1 (en) Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
JP3701675B2 (ja) ＩＦＮ−β液体製剤
JP3714951B2 (ja) Ｉｌ−６含有薬剤組成物
Piscitelli et al. Pharmacokinetic studies with recombinant cytokines: scientific issues and practical considerations
US20230078678A1 (en) Formulations of human anti-tslp antibodies and methods of treating atopic dermatitis
JP3470135B2 (ja) 成長ホルモンの結晶体を製造する方法およびそれにより得られる結晶体
JP7755766B2 (ja) 抗ｉｌ－６抗体製剤
RU2238758C2 (ru) Водный раствор интерферона-альфа-два человека для инъекций
EP2913062B1 (en) Therapeutic or prophylactic agent for retinopathy of prematurity and method of testing for retinopathy of prematurity
Mascarenhas et al. N-modulin peptides attenuate respiratory distress in a scald-endotoxemia model
Bertaglia et al. Von Willebrand factor abnormalities in IgA nephropathy.
KR20250071252A (ko) 저 투여량 il-6 제형 및 이의 사용 방법
CN112986576A (zh) 从δg的浓度依赖性来测定蛋白质聚集
US20050148507A1 (en) Method for the production of an N-terminally modified chemotactic factor
TW202409072A (zh) 用於治療個體的α－１抗胰蛋白酶（ＡＡＴ）缺乏症之方法的重組絲胺酸蛋白酶抑制劑（ｓｅｒｐｉｎ）－Ｆｃ融合蛋白之有效劑量
HK40037264A (en) Stable aqueous formulations of adalimumab